Pluristem Therapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 230.58%. Acorda Therapeutics has a consensus target price of $21.83, suggesting a potential downside of 6.50%. Given Pluristem Therapeutics ...
more»